MedTrace Logo

Prophylactic Administration of Levosimendan in Patients Undergoing Coronary Surgery

NCT01318460 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2019-05-07

No results posted yet for this study

Summary

The present pilot study aims to investigate the effectiveness of the preoperative infusion of levosimendan in patients with impaired left ventricular function undergoing coronary artery bypass grafting.

Conditions

Interventions

DRUG

Levosimendan infusion

Prophylactic 24h infusion of levosimendan at a dose of 0.1 mg/kg/min

DRUG

Placebo infusion

Twenty-four hour administration of placebo

Sponsors & Collaborators

  • Orion Corporation, Orion Pharma

    collaborator INDUSTRY

  • AHEPA University Hospital

    lead OTHER

Principal Investigators

  • Kyriakos Anastasiadis, MD, FETCS · AHEPA University Hospital

  • Christos Papakonstantinou, MD · AHEPA University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-03-31
Primary Completion
2014-03-31
Completion
2014-03-31

Countries

  • Greece

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01318460 on ClinicalTrials.gov